Press Releases Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/04/2026 BST			5-day change	1st Jan Change
87.71 ^USD	+1.82%		+3.13%	+12.72%

04-13	Kymera Therapeutics Wins FDA Fast Track for Oral Asthma Drug	MT
04-13	Kymera Therapeutics, Inc. Announces U.S. FDA Fast Track Designation for KT-621, A First-In-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma	CI

Press Releases

04-13	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma	AQ
04-09	Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate	AQ
03-30	Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology Annual Meeting	AQ
03-28	Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting	AQ
03-11	Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology Annual Meeting	AQ
03-10	Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting	AQ
02-26	Kymera Therapeutics : Corporate Presentation, February 2026	PU
02-26	Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update	AQ
02-24	Kymera Therapeutics to Participate in Upcoming March Investor Conferences	AQ
02-19	Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026	AQ
02-04	Kymera Therapeutics to Participate in Upcoming February Investor Conferences	AQ
01-29	Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader	AQ
01-13	Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs	AQ
01-06	Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13	AQ
12-11	Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	AQ
12-11	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis	AQ
12-10	Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering	AQ
12-08	Kymera Therapeutics Announces Proposed Public Offering	AQ
12-08	Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025	AQ
12-08	Kymera Therapeutics : Corporate Presentation, December 2025	PU
12-08	Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis	AQ
12-05	Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025	AQ
11-25	Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader	AQ
11-24	Kymera Therapeutics to Participate in Upcoming December Investor Conferences	AQ
11-04	Kymera Therapeutics : Corporate Presentation, November 2025	PU